Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist

References

• . Centers for Disease Control and Prevention. Number (in millions) of civilian, noninstitutionalized adults with diagnosed diabetes, United States, 1980–2011. http://www.cdc.gov/diabetes/statistics/prev/national/figadults.htm. Accessed August 20, 2014
   Google Scholar
• . International Diabetes Federation. The global burden. IDF Diabetes Atlas, 6th ed. http://www.idf.org/sites/default/files/EN_6E_Ch2_the_Global_Burden.pdf. Accessed September 9, 2014
   Google Scholar
• . Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed August 20, 2014
   Google Scholar
• . Pyke C, Heller RS, Kirk RK,. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280–1290
   PubMed Web of Science ®Google Scholar
• . Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358(3):219–224
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46–52
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54(1):10–18
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at nearphysiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76(4):912–917
   PubMed Web of Science ®Google Scholar
• . Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–1131
   PubMed Web of Science ®Google Scholar
• . Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122( 6 Suppl):S3–S10
   PubMed Web of Science ®Google Scholar
• . Verspohl EJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev. 2012;64(2):188–237
   PubMed Web of Science ®Google Scholar
• . Matthews JE, Stewart MW, De Boever EH,. Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(12):4810–4817
   PubMed Web of Science ®Google Scholar
• . Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80(3):952–957
   PubMed Web of Science ®Google Scholar
• . Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes. 2004;53(9):2492–2500
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Stewart MW. Albiglutide: glucagon-like peptide GLP-1 receptor agonist, treatment of type 2 diabetes. Drugs Future. 2010;35(9):701–712
   Web of Science ®Google Scholar
• . Reusch J, Stewart M, Perkins C,. HARMONY 1 results at week 52 primary endpoint: once-weekly albiglutide vs placebo in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin. Diabetologia. 2013;56( 1 suppl):S359–S360
   PubMed Web of Science ®Google Scholar
• . Reinhardt R, Nauck MA, Stewart M,. HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2013;56( 1 suppl):S360
   Web of Science ®Google Scholar
• . Pratley R, Stewart M, Cirkel D, Ye J, Perry C, Carr MC. HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus. Diabetologia. 2013;56( 1 suppl):S360–S361
   Web of Science ®Google Scholar
• . Pratley RE, Nauck MA, Barnett AH,. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–297
   PubMed Web of Science ®Google Scholar
• . Stewart M, Home P, Yang F, Perry C, Carr MC. 52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study. Diabetologia. 2013;56( 1 suppl):S361
   Web of Science ®Google Scholar
• . Leiter LA, Carr MC, Stewart M,. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study [published online ahead of print July 21, 2014]. Diabetes Care. No doi available
   Google Scholar
• . Rosenstock J, Fonseca V, Gross JL,. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist versus thrice daily prandial insulin lispro [published online ahead of print June 4, 2014]. Diabetes Care. doi:10.2337/dc14–0001
   Google Scholar
• . Ahren B, Johnson SL, Stewart M,. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141–2148
   PubMed Web of Science ®Google Scholar
• . GlaxoSmithKline. Tanzeum (albiglutide) for injection [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline LLC; 2014
   Google Scholar
• . Bush MA, Matthews JE, De Boever EH,. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11(5):498–505
   PubMed Web of Science ®Google Scholar
• . Young MA, Wald JA, Matthews JE, Yang F, Reinhardt RR. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide. Postgrad Med. 2014;126(3):35–46
   PubMed Web of Science ®Google Scholar
• . Darpo B, Zhou M, Matthews J,. Albiglutide does not prolong QTc interval in healthy subjects: a thorough ECG study. Diabetes Ther. 2014;5(1):141–153
   PubMed Web of Science ®Google Scholar
• . GlaxoSmithKline. A single-blind, randomized, placebo-controlled study in healthy men and women to determine the effect of single subcutaneous injections of GSK716155 on gastric emptying time for solid and liquid components of a meal [protocol summary]. http://www.gsk-clinicalstudyregister.com/study/GLP107030#ps. Accessed August 20, 2014
   Google Scholar
• . Bush M, Scott R, Watanalumlerd P, Zhi H, Lewis E. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012;124(6):55–72
   PubMed Web of Science ®Google Scholar
• . GlaxoSmithKline. An open-label, sequential study to evaluate the pharmacokinetics of simvastatin when coadministered with albiglutide in healthy adult subjects [protocol summary]. http://www.gsk-clinicalstudyregister.com/study/108366#ps. Accessed August 20, 2014
   Google Scholar
• . Seino Y, Nakajima H, Miyahara H,. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009;25(12):3049–3057
   PubMed Web of Science ®Google Scholar
• . GlaxoSmithKline. A multidose study in subjects with type 2 diabetes mellitus to assess the pharmacokinetics and pharmacodynamics of albiglutide [protocol summary]. http://www.gsk-clinicalstudyregister.com/study/114856#ps. Accessed August 20, 2014
   Google Scholar
• . Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. The potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32(10):1880–1886
   PubMed Web of Science ®Google Scholar
• . Seino Y, Inagaki N, Miyahara H,. A randomized dose-finding study demonstrating efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014;30(6):1095–1106
   PubMed Web of Science ®Google Scholar
• . Hompesch M, Jones-Leone A, Carr MC,. Albiglutide does not impair the counter-regulatory hormone response to hypoglycemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus [published online ahead of print September 26, 2014]. Diabetes Obes Metab. doi:10.1111/dom.12398
   Google Scholar
• . Wald JA, Young MA, Reinhardt R, Budda B, Watanalumlerd P, Smith C. Population PK/PD of albiglutide [abstract]. Presented at the 2014 American Conference on Pharmacometrics Meeting, October 12–15, 2014, Las Vegas, NV. J Pharmacokinet Pharmacodyn. 2014
   Google Scholar
• . Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem. 2012;3(4):73–92
   PubMedGoogle Scholar
• . US Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Information. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations. March 2003. Silver Spring, MD: CDER Division of Drug Information. http://www.fda.gov/downloads/Drugs/…/Guidances/ucm070124.pdf. Accessed August 20, 2014
   Google Scholar
• . McLennan DN, Porter CJH, Charman SA. Subcutaneous drug delivery and the role of the lymphatics. Drug Discov Today. 2005;2(1):89–96
   Google Scholar
• . Lin JH. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr Drug Metab. 2009;10(7):661–691
   PubMed Web of Science ®Google Scholar
• . Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–1095
   PubMed Web of Science ®Google Scholar
• . Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8(2):385–401
   PubMed Web of Science ®Google Scholar
• . Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52( 1 Suppl):54S–62S
   PubMed Web of Science ®Google Scholar
• . Katz J, Rosenfeld S, Sellers AL. Sites of plasma albumin catabolism in the rat. Am J Physiol. 1961;200(6):1301–1306
   PubMed Web of Science ®Google Scholar
• . Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol. 2007;122(2):146–155
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry R, Ratner R,. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Johnson S, Nuack MA, Zhi H, Weston C, Russo C, Holland C. Integrated phase 3 immunogenicity results for albiglutide. Diabetes. 2014;63( Suppl 1):A427
   Web of Science ®Google Scholar
• . Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab. 1980;51(3):520–528
   PubMed Web of Science ®Google Scholar
• . Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diabetes Vasc Dis Res. 2012;9(2):95–108
   PubMed Web of Science ®Google Scholar
• . Darpo B, Sager P, Macconell L,. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol. 2012;75(4):979–989
   Web of Science ®Google Scholar
• . Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3(1):e001986
   PubMed Web of Science ®Google Scholar
• . Sivertsen J, Rosenmeier J, Holst JJ, Vilsboll T. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol. 2012;9(4):209–222
   PubMed Web of Science ®Google Scholar
• . Centers for Disease Control and Prevention. 2014 National Chronic Kidney Disease Fact Sheet. http://www.cdc.gov/diabetes/pubs/fact-sheets/kidney.htm. Accessed August 20, 2014
   Google Scholar
• . Patel A, MacMahon S, Chalmers J,. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9(5):529–550
   PubMed Web of Science ®Google Scholar
• . Herrington WG, Nye HJ, Aung T. Metformin use in chronic kidney disease: new evidence to guide dosing. QJM. 2013;106(11):1059–1061
   PubMed Web of Science ®Google Scholar
• . Martinez-Castelao A, Gorriz JL, Sola E,. About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes. Nefrologia. 2012;32(4):419–426
   PubMed Web of Science ®Google Scholar
• . Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br J Clin Pharmacol. 2010;70(6):807–814
   PubMed Web of Science ®Google Scholar
• . Meier JJ, Gallwitz B, Salmen S,. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719–2725
   PubMed Web of Science ®Google Scholar
• . Horowitz M, Flint A, Jones KL,. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Diabetes Res Clin Pract. 2012;97(2):258–266
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561–1565
   PubMed Web of Science ®Google Scholar
• . Kothare PA, Soon DK, Linnebjerg H,. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45(9):1032–1037
   PubMed Web of Science ®Google Scholar
• . Malm-Erjefalt M, Ekblom M, Brondsted L, Vouis J, Lennernas H, Zdravkovic M. A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes. 2008;57( Suppl 1):A130
   Web of Science ®Google Scholar
• . Soon D, Kothare PA, Linnebjerg H,. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46(10):1179–1187
   PubMed Web of Science ®Google Scholar
• . Kothare PA, Linnebjerg H, Skrivanek Z,. Exenatide effects on statin pharmacokinetics and lipid response. Int J Clin Pharmacol Ther. 2007;45(2):114–120
   PubMed Web of Science ®Google Scholar
• . Kothare PA, Seger ME, Northrup J, Mace K, Mitchell MI, Linnebjerg H. Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial. BMC Clin Pharmacol. 2012;12(1):8
   PubMedGoogle Scholar
• . Jacobsen LV, Vouis J, Hindsberger C, Zdravkovic M. Treatment with liraglutide—a once-daily GLP-1 analog—does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. J Clin Pharmacol. 2011;51(12):1696–1703
   PubMed Web of Science ®Google Scholar